Naomi Dempsey, MD

Articles

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

September 26th 2023

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Utility of Primary Tumor Surgery for De Novo Metastatic Breast Cancer

September 26th 2023

Experts debate the utility of surgery on the primary tumor in patients with novel metastatic HR+/HER- breast cancer.

Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer

September 19th 2023

The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.

Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

September 19th 2023

Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.

Frontline CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

September 13th 2023

Naomi Dempsey, MD, reviews data on the use of CDK4/6 inhibitors for the frontline treatment of metastatic HR+/HER- breast cancer.

Monitoring and Treating Lymphedema in Patients With HR+/HER- Breast Cancer

September 13th 2023

Nadia Nocera Zachariah, MD, explains why early detection and monitoring of lymphedema is crucial in patients with HR+/HER- breast cancer, with technologies like prophylactic compression sleeves and nighttime compression systems showing promise in reducing negative impact on quality of life.

Updates in Adjuvant Therapy for HR+/HER- Breast Cancer From ASCO 2023: The NATALEE Trial

September 6th 2023

Dr Naomi Dempsey shares the study design, primary outcome data, and the 3-year invasive disease-free survival follow-up data from the NATALEE trial in HR+/HER2- breast cancer presented at ASCO 2023.

Helping Patients With HR+/HER2- Breast Cancer Access Abemaciclib

September 6th 2023

Experts explain the challenges patients with HR+/HER- breast cancer face in accessing abemaciclib for treatment and the options available such as patient assistance programs for high co-pays.

Considerations for Chemotherapy Dosing in Patients With HR+/HER- Breast Cancer

August 30th 2023

The panel discusses the importance of careful chemotherapy dosing and management of side effects for patients with HR+/HER- breast cancer, including the use of cooling and compression gloves to prevent peripheral neuropathy.

Clinical Scenario: A 60-Year-Old Woman With Newly Diagnosed Breast Cancer

August 30th 2023

Naomi Dempsey, MD, presents the clinical scenario of a 60-year-old woman with newly diagnosed HR+/HER- breast cancer to the panel for discussion.

Barriers to Optimal Care in Patients With HR+/HER- Breast Cancer

August 22nd 2023

Key opinion leaders detail various barriers to optimal care for patients with HR+/HER2- breast cancer, including transportation issues, financial difficulties, lack of family support, and challenges in coordinating care among different medical specialists.

Importance of Multidisciplinary Care for Patients With HR+/HER- Breast Cancer

August 22nd 2023

A panel of experts explains the importance of a multidisciplinary team in treating HR+/HER2- breast cancer to ensure comprehensive and coordinated care throughout the patient's journey.